Sort   by:  
 Page size 
UnknownRTEL1 is required for silencing and epigenome stability.
Not available
S-EPMC10484728 | biostudies-literature
GenomicsChIP-seq of histone marks (H3K27me1, H3K27me3, H3K9me2) and of the H2A.W histone variant in Arabidopsis pol2a mutants.
DNA replication requires the faithful propagation of both genetic and epigenetic information. There is evidence that DNA polymerases play a role in transcriptional silencing, but the extent of their contribution and how it relates to heterochromatin maintenance is unclear. Analyzing a new hypomorphi...
ORGANISM(S): Arabidopsis thaliana 
2020-10-18 | E-MTAB-9046 | biostudies-arrayexpress
GenomicsInstitut Curie Neuroblastoma data access Committee
Data Access Committee EGAC00001000319
EGAC00001000319 | EGA
TranscriptomicsAssessing the importance of target type for oligonucleotide microarray experiments
In order to assess the effect on signal variability of the type of target used for oligonucleotide microarray experiments, we hybridized double and single stranded DNA of three genes on a Nimblegen High Density microarray. This slide carries specific probes (two lengths: 30 and 50 nucleotides, for a...
ORGANISM(S): Dehalococcoides sp. VS 
2010-07-27 | E-GEOD-23168 | biostudies-arrayexpress
ProteomicsTEAD inhibitor K-975 enhances KRASG12C inhibitor adagrasib-mediated cancer cell proliferation inhibition via dual cell cycle arrest
Here we investigate the effect of the dual inhibition, in KRASG12C mutated NSCLC cells, using the KRASG12Ci adagrasib (MRTX849) and the pan-TEAD inhibitor (TEADi) K-975. We show that K-975 enhances adagrasib-induced tumor cell growth inhibition in cancer cells. Mechanistically, we detect a downregul...
ORGANISM(S): Homo Sapiens (human) 
2023-05-12 | PXD039726 | JPOST Repository
Genomicsena-DATASET-AMC-11-05-2015-14:58:16:693-185 - samples
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAD00001001360 | EGA
Genomicsena-DATASET-CURIE-LC-04-05-2015-16:47:47:270-89 - samples
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAD00001001356 | EGA
GenomicsInstitut Curie Neuroblastoma Whole Genome Sequencing Diagnosis Relapse
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAS00001001184 | EGA
GenomicsNeuroblastoma relapse trio series from the AMC
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAS00001001183 | EGA
GenomicsAMC Dept. Oncogenomics
Data Access Committee EGAC00001000321
EGAC00001000321 | EGA
Sort   by:  
 Page size